‘Hope And Scientific Spillover’ – Cross-Atlantic HTA Alliance To Focus On Novel Benefits

 
• By Francesca Bruce
  
The first guidance to be delivered by the HEMA HTA collaboration will help HTAs analyze the value of drugs by considering novel treatment benefits.

More from Pink Sheet

More from Health Technology Assessment